国药集团工业有限公司廊坊分公司
- Country
- Ownership
- -
- Established
- 2004-09-03
- Employees
- -
- Market Cap
- -
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
14
NMPA:14
Drug Approvals
Remifentanil Hydrochloride for Injection
- Product Name
- 注射用盐酸瑞芬太尼
- Approval Number
- 国药准字H20123422
- Approval Date
- Jul 28, 2022
NMPA
Remifentanil Hydrochloride for Injection
- Product Name
- 注射用盐酸瑞芬太尼
- Approval Number
- 国药准字H20123421
- Approval Date
- Jul 28, 2022
NMPA
Fentanyl Citrate Injection
- Product Name
- 枸橼酸芬太尼注射液
- Approval Number
- 国药准字H20123298
- Approval Date
- Jun 17, 2022
NMPA
Fentanyl Citrate Injection
- Product Name
- 枸橼酸芬太尼注射液
- Approval Number
- 国药准字H20123297
- Approval Date
- Jun 17, 2022
NMPA
Sufentanil Citrate Injection
- Product Name
- 枸橼酸舒芬太尼注射液
- Approval Number
- 国药准字H20203712
- Approval Date
- Dec 25, 2020
NMPA
Sufentanil Citrate Injection
- Product Name
- 枸橼酸舒芬太尼注射液
- Approval Number
- 国药准字H20203713
- Approval Date
- Dec 25, 2020
NMPA
Dexmedetomidine Hydrochloride Injection
- Product Name
- 盐酸右美托咪定注射液
- Approval Number
- 国药准字H20203335
- Approval Date
- Jul 21, 2020
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
No trials found
News
No news found